The Promise of Immunotherapy in the Management of Advanced Cutaneous Squamous Cell Carcinoma (CSCC): What Managed Care Needs to Know 

A continuing medical education activity sponsored by NAMCP and AAMCN 

This webinar series will provide critical updates on the advances in immunotherapies, including how to translate the most recent data into clinical and administrative practice. 

These are archives of live webinars held between May 15 to May 22, 2019.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

 By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

Each session has its own specific valid dates

This series is supported by an educational grant from Regeneron Pharmaceuticals 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  

 To print or save your certificate, you will need to click on the “download” button and either print or save.

 These presentations require Adobe Flash Player.  You can download it here.



Cutaneous squamous-cell carcinoma (CSCC) is the second-most common cancer of the skin, usually occurring in areas exposed to the sun. Sunlight exposure and immunosuppression are the main risk factors for CSCC, with chronic sun exposure being the strongest environmental risk factor. Approximately 2.2 million people have CSCC at any given time and it makes up around 20% of all skin cancer cases. While prognosis is usually good, if distant spread occurs five-year survival is approximately 34%. In 2016, it resulted in about 51,900 deaths globally. Current treatment response rates in patients with CSCC are suboptimal, with a minority of patients experiencing complete or partial response with present pharmacologic treatment options. Moreover, surgeries to remove tumors can be disfiguring, and elderly patients often are not candidates for chemotherapeutic agents because they cannot tolerate the toxicities.

Fortunately, novel immunotherapies including PD-1 inhibitors, have shown improved safety and efficacy for patients with metastatic disease. These treatments have recently become available and are providing clinicians alternative options to improve both outcomes and quality of life in patients with advanced CSCC.

A Deeper Look into Immunotherapies in the Management of Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Improving Clinical and Economic Outcomes
  • Identify current unmet clinical needs in the management of advanced cutaneous squamous-cell carcinoma (CSCC) and evidence-based recommendations for the care of patients with these tumors
  • Examine the role of the PD-1 pathway and T-cell activity in the pathophysiology of CSCC
  • Analyze the efficacy and safety of recently approved and emerging immunotherapies in the management of advanced CSCC
  • Identify of patients with advanced CSCC who would potentially benefit from immunotherapies in advanced CSCC
  • Discuss individualized CSCC treatment strategies, taking into consideration risks and benefits of therapies, patient characteristics, patient quality of life, and patient preference
Physician, Nursing and CMCN credits valid to June 1, 2021
Improving Patient Adherence and Quality of Life in Advanced CSCC: Anticipating and Managing Adverse Events
  • Examine challenges to patient adherence and quality of life in the use of immunotherapies in CSCC
  • Identify strategies for anticipating, recognizing, and managing adverse events of immunotherapy in patients with CSCC
  • Discuss methods to communicate effectively with CSCC patients and the multidisciplinary team to understand and address the needs of each patient around immunotherapy and improve treatment adherence and quality of life
  • Explore recent clinical trial data around adverse events associated with recently approved and emerging immunotherapies and their effect on patient quality of life
  • Review how treatment strategies can be affected by adverse events based on patient's individualized needs
Physician, Nursing and CMCN credits valid to June 1, 2021
Comparative Effectiveness and Coordinated Care in Advanced CSCC: What Does Managed Care Need to Know about Immunotherapies?
  • Identify key economic challenges surrounding management of patients with Cutaneous Squamous Cell Carcinoma (CSCC)
  • Discuss the managed care considerations of current and emerging immunotherapies by exploring where these agents fit into the current advanced CSCC management paradigm
  • Analyze strategies used by managed care organizations to facilitate high quality care for members with CSCC, and how recent immunotherapy approvals will affect those strategies
  • Apply methods to enable optimal cost management of immunotherapies to be realized by multiple CSCC stakeholders including managed care organizations
Physician, Nursing and CMCN credits valid to June 1, 2021